[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100545880":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":24,"centralContacts":42,"locations":24,"responsibleParty":48,"collaborators":24,"id":52,"slug":53,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":24,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":24,"enrollmentInfo":61,"targetDuration":24,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":24,"overallStatus":70,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":24},{"fullName":5,"class":6},"New Valley University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Immunocompromised ICU patients","EXPERIMENTAL","Immunocompromised ICU Patients with Respiratory tract infections",[13,14,15,16,17],"Diagnostic Test: Complete blood count","Diagnostic Test: C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)","Radiation: CT chest","Diagnostic Test: Microscopic examination","Diagnostic Test: culture and sensitivity",[19,25,29,34,38],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DIAGNOSTIC_TEST","Complete blood count","blood sample",[9],null,{"type":20,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"C-reactive protein, urea, creatinine, Random blood glucose (RBG), aspartate aminotransferase (AST), alanine aminotransferase (ALT)","serum sample",[9],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":24},"RADIATION","CT chest","Computed tomography of the chest",[9],{"type":20,"name":35,"description":36,"armGroupLabels":37,"otherNames":24},"Microscopic examination","sputum and bronchoalveolar lavage (BAL)",[9],{"type":20,"name":39,"description":40,"armGroupLabels":41,"otherNames":24},"culture and sensitivity","for bacterial and fungal",[9],[43],{"name":44,"role":45,"phone":46,"phoneExt":24,"email":47},"Asmaa N Hussein, MD","CONTACT","+2 01065161752","asmaanady_1010@med.nvu.edu.eg",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":5,"oldNameTitle":24,"oldOrganization":24},"PRINCIPAL_INVESTIGATOR","Asmaa Nady Hussein","Lecturer of Internal Medicine","100545880","characterizing-diversity-and-antifungal-resistance-in-immunocompromised-icu-patients-with-respiratory-tract-infections-100545880",false,"NCT06387667","Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","Unveiling the Fungal Frontier: Characterizing Diversity and Antifungal Resistance in Immunocompromised ICU Patients With Respiratory Tract Infections","Inclusion Criteria:\n\n* All adult patients (aged \\>18 years old) admitted to the Assiut University Hospital's intensive care units with pneumonia and hospitalized patients who developed hospital-acquired or ventilator-associated pneumonia who don't respond to antibiotics for 48 hours or with a CT finding suspected for fungal pneumonia.\n\nPatients included must have at least one of the following conditions as a contributor to immunocompromise:\n\n* Pre-existing lung disease: IPF, COPD, or sarcoidosis.\n* Immunosuppression: Neutropenia, on corticosteroids, or immunosuppressive drugs, inherited or acquired immunodeficiency.\n* Underlying comorbidities: (Diabetes Mellitus,Chronic kidney disease, Liver cirrhosis)\n* Malignancy (Hematological or solid)\n\nExclusion Criteria:\n\n* Patients refused to contribute to the study.\n* Unsatisfactory sample.","ALL","18 Years",{"count":62,"type":63},250,"ESTIMATED","INTERVENTIONAL",[66],"NA","Immunocompromised individuals face a heightened risk of life-threatening fungal infections, which arise from a multitude of environmental and commensal fungi. Surveillance data from ICUs worldwide identifies Candida spp. as the dominant foe, responsible for 80% of such infections, earning it the dubious distinction of being the third most prevalent pathogen. While C. albicans holds the dubious crown as the most common Candida offender, recent years have witnessed a concerning trend toward non-Albicans candida, raising concerns about potential antifungal resistance.",[69],"Immunocompromised ICU Patients With Respiratory Tract Infections","NOT_YET_RECRUITING","2025-08-12",{"date":73,"type":74},"2025-08-14","ACTUAL",{"date":76,"type":63},"2025-12-01",{"date":78,"type":63},"2027-06-01",{"name":5,"class":6}]